There is no effective drug to treat Alzheimer's disease (AD), a neurodegenerative disease affecting an estimated 30 million people around the world. Strongly supported by preclinical and clinical studies, amyloid-beta (Aβ) may be a target for developing drugs against AD. Meanwhile, the fact that localized neuronal death/loss and synaptic impairment occur in AD should also be considered. Neuronal regeneration, which does not occur normally in the mammalian central nervous system, can be promoted by neurotrophic factors (NTFs). Evidence from clinical trials has shown that both Aβ clearance and NTFs are potentially effective in treating AD, thus a new approach combining Aβ clearance and administration of NTFs may be an effective therapeutic strategy.
Introduction
Alzheimer's disease (AD) is an age-related, progressive and irreversible neurodegenerative disease that causes serious cognitive dysfunction. Its pathological hallmarks are extracellular deposits of amyloid-beta (Aβ) and intracellular neurofibrillary tangles, together with drastic synaptic and neuronal reduction or loss [1] . It has been estimated that AD affects 30 million people around the world [2] , and the past two decades have witnessed an explosion in research into the underlying mechanisms as well as potential therapeutic strategies. Although it was first described by German psy- [4] . Memantine, an NMDAR antagonist, has been approved for the treatment of moderate and severe AD; it works by preventing the excitatory neurotoxicity induced by excessive glutamate [5] .
Currently, no available pharmacological agents cure or reverse the progression of this devastating neurological disorder. It is therefore urgent to improve our understanding of its pathogenesis, and then develop an effective treatment strategy. This review aimed to provide insights 
Aβ as a Promising Target for AD Treatment
Aβ is a peptide of 36-43 amino-acids produced from amyloid precursor protein (APP) through aberrant cleavage by β-and γ-secretases. According to the Aβ cascade hypothesis proposed by Hardy and Selkoe, the accumulation of extracellular Aβ aggregates or senile plaques is the key causative factor in the pathological or neurodegenerative changes associated with the development of AD, including inhibition of long-term potentiation, impairment of synaptic function, and eventual neuronal death/loss leading to cognitive decline [6] [7] [8] .
Of the AD-related factors listed in Table 1 , ~50% are associated with Aβ. Although many factors are also known to be associated with AD (Table 1) , the Aβ hypothesis remains the focus of research. This is strongly supported by the observation of abundant deposits of Aβ in the brain in both sporadic AD (~95% of cases) without a clear inheritance pattern, and familial AD (~5% of cases) with autosomal dominant inheritance caused by mutations of APP and the homologous presenilin genes, presenilin 1 and 2. These mutations inevitably lead to increased levels of Aβ which is considered to be the molecule that initiates neuronal degeneration [47] . Evidence for this hypothesis comes from APP transgenic mice that show correlations between elevated Aβ, Aβ plaques and cognitive deficits.
Clinical studies of AD also support this hypothesis. RoveletLecrux et al. reported a duplication of the APP locus on chromosome 21 in five families with autosomal dominant early-onset AD [48] . Barthel et al., using positron emission tomography (PET) images of florbetaben (an 18 F-labeled Aβ-targeted PET tracer), demonstrated that nine of ten mildmoderate probable AD participants (DSM-IV and NINCDS-ADRDA criteria) were Aβ-positive, compared to only one of ten healthy controls [49] . Furthermore, in a global phase 2, open-label, non-randomized, multi-center study recruiting a total of 81 men and women with probable mild-to-moderate AD and 69 cognitively unimpaired healthy volunteers aged 55 years and older, florbetaben scans indicated a sensitivity of 80% (95% CI 71-89) and a specificity of 91% (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) (98) for discriminating participants with AD from healthy controls [50] .
In addition, Aβ has recently been reported to alter tau phosphorylation, which is associated with the other cardinal lesion of AD, neurofibrillary tangles composed primarily of hyperphosphorylated tau [51] . Zeng et al. [52] , for example, 
Aβ Downregulates NTFs
As neurotrophic effects are directly correlated with neuronal survival and the maintenance of synaptic plasticity, neurotrophic imbalance is a likely mechanism of Aβ impairment.
NTFs, such as BDNF and nerve growth factor (NGF), play critical roles in neuronal survival and regeneration as well as synaptic plasticity. More importantly, Aβ has been found to contribute to the downregulation of NTFs.
Peng et al. demonstrated that transgenic mouse models of AD harboring mutations in APP resulting in Aβ overproduction, show a significant reduction in cortical BDNF mRNA expression in comparison with wild-type mice [9] .
The cortex and hippocampus, regions involved in learning and memory, exhibit both increased Aβ production and reduced BDNF levels in AD [53] [54] [55] . Aβ may impair neurotrophic signaling by decreasing NTF levels. NTF deficiency has the same presentation as the end-point of AD, neuronal loss and synaptic dysfunction. Regionalized neuronal death/loss and synaptic impairment in the process of AD have been demonstrated in many diagnostic, clinical, and pathological studies [56] [57] [58] [59] . For example, West et al. [60] found that neurons in the CA1 region of the hippocampus decline from 14.08 × [62] . These findings provide evidence that neuroregeneration might be an approach to treat AD.
NTF Deficits Cause Aβ Overload
Recent evidence suggests that Aβ neurotoxicity may be a consequence of NTF deficiency. This is supported by the finding that the AD11 mouse model, which expresses the recombinant monoclonal antibody αD11 that specifically neutralizes NGF thus causing NGF deprivation, shows ADlike pathology including Aβ accumulation and hippocampusdependent memory deficits [63, 64] . Based on the report that activation of the amyloidogenic route by NGF deprivation induces apoptotic death in PC12 cells [65] , Matrone and colleagues further found that APP and presenilin 1 N-terminus (which is the active component endowed with γ-secretase activity) levels were increased in hippocampal neurons that were previously exposed to NGF or BDNF for 48 h followed by deprivation by anti-NGF (or -BDNF) antibodies [66] . These findings suggest that Aβ and NTF deficits cause a feedforward loop that accelerates the toxicity of Aβ sufficient to cause neuronal death.
Moreover, p75 neurotrophin receptor (p75NTR), a pan-receptor for neurotrophins including BDNF, NGF, neurotrophin-3 and neurotrophin-4/5, has been reported to correlate with Aβ production. Knockout of p75NTR in APPtransgenic mice reduces the Aβ production in the brain,
suggesting that activation of p75NTR in Aβ-related pa- , activation of inflammatory cells [10] , generation of reactive oxygen species [11] , inhibition of long-term potentiation [6] , impairment of synaptic structure and function [7, 8] , acceleration of neurofibrillary tangle formation
Altered function of blood-brain barrier Decreased clearance of Aβ [13] , leakage of serum-derived components into brain leading to neuronal dysfunction [14] , promotion of aluminum accumulation in brain [15] Brain trauma Increased risk of AD [16, 17] Chronic stress Induction of abnormal hyperphosphorylation of tau [18] , accelerated impairment of cognition [19] Decline in protein synthesis Further neuronal impairment caused by other factors [20, 21] Decline in stimulation and acetylcholine Impaired memory circuitry [22, 23] Decreased levels of neurotrophic factors Deficient support for neuronal survival [24, 25] Depression Chronic inflammation, impairment in the signaling of neurotrophins [26] Diabetes Apoptosis of neurons, defects of long-term potentiation, changed synapse plasticity [27, 28] Downregulation of neprilysin Promotion of Aβ deposits [29] [30] [31] Enhanced reactive oxygen species levels Contributes to mitochondrial dysfunction [32, 33] and calcium overload
Glutamate increases
Neuronal excitotoxicity leading to neuronal death [34, 35] Hyperphosphorylated tau Formation of neurofibrillary tangles [36, 37] Inflammation Exacerbation of tau pathology [38] , induction of Aβ release from neurons [39] , attenuation of long-term potentiation [40] , retraction of synapses [41] Metal ion dyshomeostasis Promotion of Aβ aggregation [42, 43] Mutations in genes for presenillin-1 and -2, and Increased Aβ levels, linked to Aβ accumulation [44] [45] [46] amyloid precursor protein; ApoE 4 allele genotype thologies leads to increased Aβ production [67] . This finding may well explain the sporadic AD which does not involve mutations of genes implicated in Aβ generation. In the AD brain, p75NTR expression is increased while neurotrophin levels are decreased, resulting in activation of the neurodegenerative pathway (triggered by proNGF and Aβ) that leads to Aβ overproduction, neuronal death, and finally cognitive decline, rather than activation of the neurotrophic pathway (triggered by neurotrophins) that promotes neuronal survival and improves cognition [68] . Moreover, AD11
transgenic mice with chronic NGF deprivation (that is, the transgenic anti-NGF antibodies bind to mature NGF much more strongly than to proNGF, leading to a decrease in mature NGF availability with a lower NGF/proNGF ratio)
show Aβ accumulation and cognitive decline, for which the "neurotrophic deficit" hypothesis was recently refined as "neurotrophin imbalance" [63] . Interestingly, by crossing anti-NGF mice to p75NTR exonIII(−/−) mice, Capsoni reported a full rescue of anti-NGF mice with the Aβ phenotype by p75NTR
signaling abrogation [69] . It would thus be reasonable to patients with mild-moderate AD in a phase 2 clinical trial [70] .
Exploratory analyses in another phase 2 trial of bapineuzumab in mild-moderate AD showed that potential treatment difference was found for 79 APOE ε4 noncarriers (47 bapineuzumab vs 32 placebo) and for completers (defined as patients who completed all bapineuzumab treatment and a week 78 efficacy assessment in this trial, 36 bapineuzumab vs 21 placebo) [71] . Bapinneuzumab is now under- [73] [74] [75] , and for tramiprosate, which targets the production of Aβ [76] .
Therefore, a question arises as to why Aβ clearance for AD treatment seems not as effective as predicted by the Aβ hypothesis. One could argue that AD researchers should think outside Aβ box [77] . However, these failures do not predict the future, as proposed by Selkoe. On one hand, the failures of these experimental drugs may be due to their intrinsic drawbacks. Tarenflurbil is a weak γ-secretase modulator (~250 µmol/L half-maximal inhibitory concentration) with poor brain penetration [78] . Semagacestat is a non-selective γ-secretase inhibitor with a therapeutic index of <3; its half-maximal inhibitory concentration for
Aβ reduction is only two to three times lower than that for inhibiting Notch cleavage [79] , a receptor involved in regulating cell-fate decisions. Deficient Notch signaling is a severe side-effect of γ-secretase inhibitors; it can cause abnormalities in the gastrointestinal tract, thymus and spleen [80] .
Besides, none of these experimental drugs showed enough potential disease-modifying of AD in phase 2 clinical trial but they were nevertheless advanced to phase 3 clinical trial [81] , which could in part account for this status quo of Aβ clearance treatment. On the other hand, anti-Aβ therapies may be highly effective in preventing or slowing the progress of AD in asymptomatic patients with very early signs of AD pathology (that is, presymptomatic phases of AD are likely to benefit from anti-Aβ therapies) [82] .
Other Therapeutic Approaches to AD
In addition to Aβ, microtubule-associated protein tau, the hyperphosphorylation of which contributes to axonal transport disruption and the accumulation of neurofibrillary tangles [83] , is also an important therapeutic target for AD.
As dysregulation of tau processing causes neuronal degeneration correlated with AD [84] , researchers have made substantial efforts to search for targets to reverse abnormal tau processing. To date, several kinases have been identified as key players in abnormal tau phosphorylation, particularly glycogen synthase kinase 3 (GSK-3) and protein phosphatase 2A [85] . The role of GSK-3 in the development of AD-like cognitive decline was supported by Liu et al. [86] who found that inhibition of phosphoinositol-3 kinase and protein kinase C results in overactivation of GSK-3, leading to tau hyperphosphorylation and eventually impaired spatial memory. Lithium, a GSK-3 inhibitor, has been shown to reduce the amount of altered tau protein in animal studies and improve cognitive and biological outcomes in participants with amnestic mild cognitive impairment in a phase 2 clinical study [87] .
Besides, since inflammation may participate in the neurodegenerative process of AD, the use of non-steroidal anti-inflammatory medications such as naproxen may reduce AD incidence in vulnerable subjects [88] . Oxidative stress is also reported to play a role in the process of AD, as strongly proposed by Smith and Perry [89, 90] , and antioxidants may be associated with a lower risk of AD [91] . These treatment strategies for AD are still under way and more investigations and trials are needed to test their efficacy in its prevention or treatment.
Perspectives
Currently, a major problem we have to combat is that patients with AD do not receive interventional treatment until it has already developed to a level at which neurons have already been so disrupted that, we think, targeting Aβ alone is insufficient to cure the disease. Previous attempts using the approach of Aβ clearance decreased Aβ levels in the (CNS), a phenomenon that has been well documented [92] .
Under normal circumstances, very few, if any, axons in the CNS can regenerate past a lesion site where distinctive large endings (retraction bulbs) are found [93] .
There is a metaphor that vividly elucidates the failure of targeting Aβ to treat AD. Suppose a mouse runs into a house and chews through the electrical circuit for lighting the house, then the light bulbs associated with this circuit will be off due to the failure of power. A mousetrap is used to catch the mouse to prevent further impairment of the circuit. If the broken circuit is not repaired, the light bulb is still off even though the mouse has been captured.
Not only should the mouse be captured, but the broken circuit should be fixed in order to make the light work. In this image, we metaphorically take the mouse to be Aβ, the mousetrap to be Aβ clearance, the electrical circuit as neuronal networks, and the light bulb as cognitive function.
From the point of view of this metaphor, treatment of AD by combining Aβ clearance with neuroregeneration may be beneficial.
NTFs Promote Neuroregeneration
There is ample and encouraging evidence that NTFs stimulate neuronal growth, increase synapse number and promote the survival of mature mammalian CNS neurons [94] [95] [96] .
A study by Nagahara et al. [97] showed that BDNF prevents the lesion-induced death of entorhinal cortical neurons in aged rats and reverses the synaptic loss in APP transgenic mice. It has also been demonstrated that NGF has a trophic influence on the basal forebrain cholinergic neurons whose pronounced loss is responsible for the cognitive decline in AD [98] . In view of the potential therapeutic effects of NTFs on degenerating neurons, efforts have been made to use them to treat AD [99] . Since the first discovery of NGF in the 1950s, a variety of chemical compounds that possess neurotrophic activity, such as magnesium fructose 1, 6-diphosphate [100] , magnolol and honokiol [101] , have been identified. The known ability of these compounds or factors to promote nerve regeneration and neuronal survival has made them a highly attractive group of targets for developing drugs for AD.
There are also encouraging outcomes from clinical trials using neurotrophic agents to treat AD. Cerebrolysin is a peptide preparation acting in a way similar to endog- The severity of neuronal/synaptic loss varies at different stages of AD. Synaptic loss in CA1 in mild AD plummets to 55% that of groups with mild cognitive impairment (MCI) or no cognitive impairment (NCI), while the synaptic value in CA1 of the MCI brain decreases by 18% of that in NCI brain [105] . Rossler et al. found that, according to the Braak staging system, neuron density in CA1 is reduced by 33%
at stage IV (P <0.02) and 51% at stage V (P <0.000 2) in comparison with stage I during AD [104] . These data suggest a strong correlation between neuronal/synaptic loss and severity of decline in cognition. Such loss may influence the efficacy of anti-Aβ on treating AD. This might well explain why anti-Aβ therapies have a high efficacy in preventing and delaying the development of AD in early stages of the disease, but are much less effective in advanced stages [106] .
Thus, neuroregeneration agents may enable anti-Aβ to have high efficacy in the advanced stage.
Ideally, these two approaches can be combined to ameliorate the pathological process of AD or better still to improve cognitive function in AD patients. Different from the specific reduction of Aβ neurotoxicity by Aβ clearance, NTFs target and act through various receptors on a range of injured or degenerating neurons. It is therefore likely that the protective or rescuing effects of the two mechanisms can be synergistic, and may be more effective for the treatment of AD. This indeed has been reiterated by Chopra et al. [107] : "a synergistic combination of agents will have the capacity to alter the neurodegenerative cascade and the major aim should be to design ligands with pluripotent pharmacological activities".
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